Recent clinical trials in atrial fibrillation in hypertensive patients

Current Hypertension Reports

Volumn 14, Issue 4, 2012, Pages 350-359

  Manolis, Athanasios J ^a   Kallistratos, Manolis S ^a   Poulimenos, Leonidas E ^a  

^a IASO GENERAL HOSPITAL   (Greece)

Author keywords

Anticoagulation treatment; Apixaban; Atrial fibrillation; CHA2DS2 VASc score; CHADS2 score; Dabigatran; Dronedarone; Eplerenone; HAS BLED score; Hypertension; RAS blockers; Rivaroxaban; Vernakalant; Vitamin K antagonists

Indexed keywords

ACETYLSALICYLIC ACID; ALDOSTERONE ANTAGONIST; AMIODARONE; AMLODIPINE; ANGIOTENSIN RECEPTOR ANTAGONIST; ANTICOAGULANT AGENT; ANTIHYPERTENSIVE AGENT; ANTIVITAMIN K; APIXABAN; ATENOLOL; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CALCIUM CHANNEL BLOCKING AGENT; CANDESARTAN; DABIGATRAN; DILTIAZEM; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DIURETIC AGENT; DRONEDARONE; EPLERENONE; LOSARTAN; PLACEBO; RAMIPRIL; RIVAROXABAN; SOTALOL; TELMISARTAN; UNINDEXED DRUG; VALSARTAN; VERAPAMIL; VERNAKALANT; WARFARIN;

ARTICLE; BLEEDING; BRAIN HEMORRHAGE; CLINICAL TRIAL (TOPIC); DISEASE ASSOCIATION; DRUG DOSE COMPARISON; DRUG EFFICACY; DRUG FATALITY; DRUG SAFETY; DRUG TOLERABILITY; EMBOLISM; HEART ATRIUM FIBRILLATION; HEART FAILURE; HEART INFARCTION; HEART PROTECTION; HOLTER MONITORING; HUMAN; HYPERTENSION; LUNG EMBOLISM; MEDICAL DECISION MAKING; OUTCOME ASSESSMENT; PACEMAKER; PREDICTION; RECURRENT DISEASE; RISK ASSESSMENT; RISK BENEFIT ANALYSIS; RISK FACTOR; STROKE;

ANTICOAGULANTS; ANTIHYPERTENSIVE AGENTS; ATRIAL FIBRILLATION; DISEASE PROGRESSION; FIBRINOLYTIC AGENTS; HUMANS; HYPERTENSION; RENIN-ANGIOTENSIN SYSTEM; RISK FACTORS; WARFARIN;

EID: 84865644412     PISSN: 15226417     EISSN: 15343111     Source Type: Journal    
DOI: 10.1007/s11906-012-0268-5     Document Type: Article

References (48)

1. Go AS, Hylek EM, Phillips KA, et al. Prevalence of diagnosed atrial fibrillation in adults: National implications for rhythm management and stroke prevention: The anticoagulation and risk factors in atrial fibrillation (ATRIA) study. JAMA. 2001;285:2370-5. (Pubitemid 32424106)
2. Wattigney WA, Mensah GA, Croft JB, et al. Increasing trends in hospitalization for atrial fibrillation in the USA, 1985 through 1999; implications for primary prevention. Circulation. 2003;108:711-6. (Pubitemid 36999256)
3. Benjamin EJ, Levy D, Vaziri SM, et al. Independent risk factors for atrial fibrillation in a population-based cohort. The Framingham Heart Study. JAMA. 1994;271:840-4.
4. Connolly SJ, Ezekowitz MD, Yusuf S, et al. Dabigatran versus warfarin in patients with atrial fibrillation. N Engl J Med. 2009;361:1139-51. Major II inhibitor Dabigatran publication presenting the results of the RELY trial. 5. 9.
5. Patel MR, Mahaffey KW, Garg J, et al. Rivaroxaban versus warfarin in nonvalvular atrial fibrillation. N Engl J Med. 2011;365:883-91.
6. Granger CB, Alexander JH, McMurray JJ, et al. Apixaban versus warfarin in patients with atrial fibrillation. N Engl J Med. 2011;365:981-92. Major Xa inhibitor apixaban publication presenting the results of the ARISTOTLE trial.
7. Benjamin EJ, Wolf PA, D'Agostino RB, Silbershatz H, Kannel WB, Levy D. Impact of atrial fibrillation on the risk of death: The Framingham Heart Study. Circulation. 1998;98:946-52. (Pubitemid 28446646)
8. Wolf PA, Abbott RD, Kannel WB. Atrial fibrillation as an independent risk factor for stroke: The Framingham Study. Stroke. 1991;22:983-8.
9. Go AS. The epidemiology of atrial fibrillation in elderly persons: The tip of the iceberg. Am J Geriatr Cardiol. 2005;14:56-61.
10. Penado S, Cano M, Acha O, et al. Atrial fibrillation as a risk factor for stroke recurrence. Am J Med. 2003;114:206-10. (Pubitemid 36294006)
11. Bunch TJ, Weiss JP, Crandall BG, et al. Atrial fibrillation is independently associated with senile, vascular, and Alzheimer's dementia. Hear Rhythm. 2010;7:433-7.
12. Savelieva I, Camm AJ. Silent atrial fibrillation-Another Pandora's box. Pacing Clin Electrophysiol. 2000;23:145-8. (Pubitemid 30108462)
13. Page RL, Tilsch TW, et al. Azimilide Supraventricular Arrhythmia Program (ASAP) Investigators. Asymptomatic or 'silent' atrial fibrillation: Frequency in untreated patients and patients receiving azimilide. Circulation. 2003;107:1141.
14. Healey JS, Connolly SJ, Gold MR, et al. Subclinical atrial fibrillation and the risk of stroke N. Engl J Med. 2012;366:120-9. Results of the ASSERT study highlighting the significance of silent or subclinical AF revealed in patients with pacemakers.
15. Schnabel RB, Aspelund T, Li G, et al. Validation of an atrial fibrillation risk algorithm in whites and African Americans. Arch Intern Med. 2010;170:1909-17.
16. Mant J, Fitzmaurice DA, Hobbs FD, et al. Accuracy of diagnosing atrial fibrillation on electrocardiogram by primary care practitioners and interpretative diagnostic software: Analysis of data from screening for atrial fibrillation in the elderly (SAFE) trial. BMJ. 2007;335:380.
17. Healey JS, Baranchuk A, Crystal E, et al. Prevention of atrial fibrillation with angiotensin-converting enzyme inhibitors and angiotensin receptor blockers: A metaanalysis. J Am Coll Cardiol. 2005;45:1832-9. (Pubitemid 40789940)
18. Kalus JS, Coleman CI, White CM. The impact of suppressing the renin angiotensin system on atrial fibrillation. J Clin Pharmacol. 2006;46:21-8. (Pubitemid 43024117)
19. Schneider MP, Hua TA, Bohm M, et al. Prevention of atrial fibrillation by renin-Angiotensin system-inhibition a meta-Analysis. J Am Coll Cardiol. 2010;55:2299-307. RAS system inhibition efficacy in AF prevention.
20. Schmieder RE, Kjeldsen SE, Julius S, et al. VALUE Trial Group. Reduced incidence of new-onset atrial fibrillation with angiotensin II receptor blockade: The VALUE trial. J Hypertens. 2008;26:403-11. (Pubitemid 351317247)
21. Wachtell K, Lehto M, Gerdts E, et al. Angiotensin II receptor blockade reduces new-onset atrial fibrillation and subsequent stroke compared to atenolol: The Losartan Intervention For End Point Reduction in Hypertension (LIFE) study. J Am Coll Cardiol. 2005;45:712-9. (Pubitemid 40282586)
22. ONTARGET Investigators, Yusuf S, Teo KK, Pogue J, et al. Telmisartan, ramipril, or both in patients at high risk for vascular events. N Engl J Med. 2008;358:1547-59. (Pubitemid 351522739)
23. Telmisartan Randomised AssessmeNt Study in ACE iNtolerant subjects with cardiovascular Disease (TRANSCEND) Investigators, Yusuf S, Teo K, Anderson C, et al. Effects of the angiotensinreceptor blocker telmisartan on cardiovascular events in high-risk patients intolerant to angiotensin-converting enzyme inhibitors: A randomised controlled trial. Lancet. 2008;372:1174-83.
24. Yusuf S, Diener HC, Sacco RL, PRoFESS Study Group, et al. Telmisartan to prevent recurrent stroke and cardiovascular events. N Engl J Med. 2008;359:1225-37.
25. Tveit A, Seljeflot I, Grundvold I, et al. Effect of candesartan and various inflammatory markers on maintenance of sinus rhythm after electrical cardioversion for atrial fibrillation. Am J Cardiol. 2007;99:1544-8. (Pubitemid 46770639)
26. GISSI-AF Investigators, Disertori M, Latini R, Barlera S, et al. Valsartan for prevention of recurrent atrial fibrillation. N Engl J Med. 2009;360:1606-17.
27. Goette A, Schön N, Kirchhof P, et al. Angiotensin II-Antagonist in Paroxysmal Atrial Fibrillation (ANTIPAF)-Trial. Circ Arrhythm Electrophysiol. 2012;5:43-51.
28. Nasr IA, Bouzamondo A, Hulot JS, Dubourg O, Le Heuzey JY, Lechat P. Prevention of atrial fibrillation onset by beta-blocker treatment in heart failure: A meta-Analysis. Eur Heart J. 2007;28:457-62. (Pubitemid 47343566)
29. Schaer BA, Schneider C, Jick SS, Conen D, Osswald S, Meier CR. Risk for incident atrial fibrillation in patients who receive antihypertensive drugs: A nested case-control study. Ann Intern Med. 2010;152:78-84.
30. L'Allier PL, Ducharme A, Keller PF, et al. Angiotensin-converting enzyme inhibition in hypertensive patients is associated with a reduction in the occurrence of atrial fibrillation. J Am Coll Cardiol. 2004;44:159-64. (Pubitemid 38976480)
31. Zannad F, McMurray JJ, Krum H, et al. Eplerenone in patients with systolic heart failure and mild symptoms. N Engl J Med. 2011;364:11-21.
32. Kowey PR, Dorian P, Mitchell LB, for the Atrial Arrhythmia Conversion Trial Investigators, et al. Vernakalant hydrochloride for the rapid conversion of atrial fibrillation after cardiac surgery: A randomized, double-blind, placebo-controlled trial. Circ Arrhythm Electrophysiol. 2009;2:652-9.
33. Camm AJ, Capucci A, Hohnloser SH, on behalf of the AVRO Investigators, et al. A randomized active-controlled study comparing the efficacy and safety of vernakalant to amiodarone in recentonset atrial fibrillation. J Am Coll Cardiol. 2011;57:313-21. Study of Vernakalant vs Amiodarone showing enhanced efficacy of the new drug versus the current standard of care.
34. EHRA,EACTS, Camm AJ, Kirchhof P, Lip GY, et al. Guidelines for the management of atrial fibrillation: The Task Force for the Management of Atrial Fibrillation of the European Society of Cardiology (ESC). Eur Heart J. 2010;31:2369-429. Current ESC AF guidelines.
35. Connolly SJ, Camm AJ, Halperin JL, PALLAS Investigators, et al. Dronedarone in high-risk permanent atrial fibrillation. N Engl J Med. 2011;365:2268-76. The PALLAS study that raised serious points concerning the safety of Dronedarone and was prematurely terminated for these reasons. 3
36. Van Gelder IC, Groenveld HF, Crijns HJ, et al. Lenient versus strict rate control in patients with atrial fibrillation. N Engl J Med. 2010;362:1363-73. A very important study highlighting the value of less strict rate control in AF. 38. The AFFIRM Investigators. A comparison of rate control and rhythm control in patients with atrial fibrillation. N Engl J Med. 2002;347:1825-33.
37. Saksena S, Slee A, Waldo AL, et al. Cardiovascular outcomes in the AFFIRM Trial (Atrial Fibrillation Follow-Up Investigation of Rhythm Management). An assessment of individual antiarrhythmic drug therapies compared with rate control with propensity score-matched analyses. J Am Coll Cardiol. 2011; 58:1975-85.
38. Bunch TJ, Crandall BG, Weiss JP, et al. Patients treated with catheter ablation for atrial fibrillation have long-Term rates of death, stroke, and dementia similar to patients without atrial fibrillation. J Cardiovasc Electrophysiol. 2011;22:839-45.
39. Lip GY, Frison L, Halperin JL, Lane DA. Identifying patients at high risk for stroke despite anticoagulation: A comparison of contemporary stroke risk stratification schemes in an anticoagulated atrial fibrillation cohort. Stroke. 2010;41:2731-8.
40. Pisters R, Lane DA, Nieuwlaat R, et al. A novel user-friendly score (HAS-BLED) to assess 1-year risk of major bleeding in patients with atrial fibrillation: The Euro Heart Survey. Chest. 2010;138:1093-100.
41. Ogilvie IM, Newton N, Welner SA, et al. Underuse of oral anticoagulants in atrial fibrillation: A systematic review. Am J Med. 2010;123:638-45.
42. Lee S, Shafe ACE, Cowie MR. UK stroke incidence, mortality and cardiovascular risk management 1999-2008: Time-Trend analysis from the General Practice Research Database. BMJ Open. 2011;1:e000269. doi:10.1136/bmjopen-2011- 000269.
43. Wann LS, Curtis AB, Ellenbogen KA, et al. ACCF/AHA/HRS focused update on the management of patients with atrial fibrillation (update on Dabigatran): A report of the American College of Cardiology Foundation/American Heart Association Task Force on practice guidelines. Circulation. 2011;123:1144-50. The first recommendation on the use of non VKA anticoagulants for AF.
44. Shah SV, Gage BF. Cost-effectiveness of dabigatran for stroke prophylaxis in atrial fibrillation. Circulation. 2011;123:2562-70.
45. Uchino K, Hernandez AV. Dabigatran association with higher risk of acute coronary events: Meta-Analysis of noninferiority randomized controlled trials. Arch Intern Med 2012;172:397-402. Is there an increased risk of acute coronary events by the use of Dabigatran?
46. Hohnloser SH, Oldgren J, Yang S, et al. Myocardial ischemic events in patients with atrial fibrillation treated with dabigatran or warfarin in the RE-LY (Randomized Evaluation of Long-Term Anticoagulation Therapy) trial. Circulation 2012;125:669-76. Is there an increased risk of acute coronary events by the use of Dabigatran?
47. Mega JL, Braunwald E, Wiviott SD, ATLAS ACS 2-TIMI 51 Investigators, et al. Rivaroxaban in patients with a recent acute coronary syndrome. N Engl J Med. 2012;366:9-19. A positive result study on the efficacy of rivaroxaban in Acute Coronary Syndromes.
48. Alexander JH, Lopes RD, James S, APPRAISE-2 Investigators, et al. Apixaban with antiplatelet therapy after acute coronary syndrome. N Engl J Med. 2011;365(8):699-708.